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Abstract There are many acute care and preventive
medications for the treatment of migraine. However,
patients may often find that their headaches are not under
optimal control. There are several targets that have been
looked at and studied for the production of new, more
effective medications. There are also effective devices for
therapy of migraine. A list of targets will be put forth and a
small number of them will be described in greater detail in
this paper.
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Introduction
Migraine is a chronic and at times disabling disorder, usu-
ally consisting of attacks of significant headache, various
associated symptoms (i.e. nausea, vomiting, sonophobia,
photophobia and worsening with exertion) and sometimes
visual or other types of auras. It affects about 12% of the
population of the US and other Western countries. There are
several categories of acute care medications including over
the counter substances and prescription medications. They
include simple analgesics, combination analgesics,
NSAIDs, prescription analgesics, ergots and triptans.
In Europe and Canada, the first triptan was launched in
1991. In the US, it was first available in 1993 and today
there are seven triptans available with a variety of formu-
lations including tablets, injections, orally disintegrating
tablets and nasal sprays. Although triptans are usually
considered as the first-line treatment for acute care of
migraine attacks, some patients cannot afford them, over
one-third of patients do not respond ideally to triptans and
over half are willing to try other treatments than the one
they are currently taking.
There are only five preventive medications approved by
the FDA and only four of them are available in the US at this
time, two beta blockers and two antiepileptic medications.
However, none of them works in more than 50% of patients
and they all have significant possible adverse events.
There are multiple targets that form the basis for possible
new acute care and preventive treatments for migraine. This
paper will list many categories of them and concentrate on
some new drugs which may become available within the next
few years.
Categories of future acute care and preventive
medication for migraine
There are many future targets and some are being inves-
tigated as possible new therapies and others have already
led to the creation of drugs that are currently in clinical
trials [1]. What follows is a listing of future targets:
1. Calcium channel modulators
2. Sodium channel blockers (lacosamide, a slow sodium
channel blocker)
3. Glutamate blockers
4. Novel antiepileptics (SV2A blockers, e.g. levetiracetam)
5. GABA enhancers and analogs (valproate)
6. AT2 (angiotensin 2 inhibitors)
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10. Acetylcholine receptor modulators
11. BDNF modulators (brain-derived neurotrophic factor)
12. Orexin-melatonin pathway modulators
13. Dopamine antagonists delivered by oral inhalation
(prochlorperazine and loxapine)
14. Sigma receptor agonists (dextromethorphan and
others)
15. Non AMPA-kainate glutamate receptor modulators
16. Potassium current modulators
17. Chloride channel enhancers
18. Connexin hemi-channel modulators (tight junction
antagonists, e.g. tonabersat)
19. NOS inhibitors (nitric oxide synthase)
20. Arachidonic cascade modulators (COX-2 and cys-
teinyl leukotriene antagonists)
21. Astrocytic calcium wave inhibitors
22. Existing and new 5-HT1B/D/F agonists
23. CGRP antagonists (olcegepant and telcagepant)
24. Glutamate modulators (memantine and tezampanel)
25. Anti-inflammatory drugs [NSAIDs: ketorolac nasal
spray (ROX-828) and diclofenac (PRO-153)]
26. COX-3 inhibitors (dipyrone in Brazil)
27. Peripheral cannabinoid agonists (CB1 —dronabinol)





Calcitonin gene-related peptide, closely related structurally
to calcitonin and amylin, has been intensely studied over
the last 20 years as an agent possibly related to migraine
pathophysiology. CGRP is involved in sensory neuro-
transmission and can be found in most sensory nerves,
especially those trigeminovascular afferents in the menin-
ges involved in migraine [2]. It is one of the most potent
vasodilators known. CGRP levels measured in the jugular
venous system are elevated after migraine and cluster
headache attacks, and are normalized by therapy with
sumatriptan. For years, it was thought that blocking its
dilating effect might help to treat migraine and its antag-
onism held promise to be a novel strategy to relieve
migraine headache. It is now known to effectively block
migraine pain without overt vasoconstriction. If and when
they gain approval in the US by the FDA and in other
countries, CGRP receptor antagonists would be the first
non-serotonergic, non-vasoconstricting, migraine specific
medication.
CGRP has been shown to have several sites of action
including blood vessels, mast cells in the meninges and as a
facilitator of pain transmission the brain stem [3]. CGRP
receptors have been found in trigeminal ganglion, in the
brain stem in neurons of the trigeminal nucleus caudalis
and in smooth muscle of the meningeal vasculature [6].
CGRP can be blocked by a fragment of the peptide con-
taining amino acids 8-37 (CGRP 8-37). The first effective
CGRP receptor blocker was BIBN4096 (olcegepant).
It was reported that intravenous administration helped a
significant number of patients versus placebo, without
constricting blood vessels in preclinical studies [4]. Tel-
cagepant, previously termed MK-0974, was the first
reported oral formulation of a CGRP receptor antagonist. It
has been reported to work well in migraine in a phase IIB
study published in Neurology and recently in a phase III
study published in Lancet [5, 6]. Preclinical data suggest
that telcagepant is not a vasoconstrictor and clinical studies
show it to be as effective as rizatriptan and zolmitriptan
and as tolerable as placebo. It is predicted that this drug
could be launched in 2010, possibly to be followed by one
or two competitors sometime afterwards.
In the recently published article, telcagepant 300 mg
was found to be as effective as zolmitriptan with fewer
adverse events [6]. This was a randomized, parallel-
treatment, placebo and active-controlled, double-blind,
trial performed at 81 sites in Europe and the USA of
adults with migraine diagnosed by International Headache
Society criteria. Patients treated moderate or severe
migraine attacks with either oral telcagepant 150 or
300 mg, zolmitriptan 5 mg, or placebo. There were five
co-primary endpoints: pain freedom, pain relief and
absence of nausea, photophobia and phonophobia, at 2 h
after treatment.
According to Dr. Ho’s article, ‘‘1,380 patients were
randomly assigned to receive telcagepant 150 mg (n =
333), 300 mg (n = 354), zolmitriptan 5 mg (n = 345) or
placebo (n = 348). Telcagepant 300 mg was more effec-
tive than placebo for pain freedom (95 [27%] of 353
patients vs. 33 [10%] of 343 [P \ 0.0001]), pain relief (194
[55%] of 353 vs. 95 [28%] of 343 [P \ 0.0001]), and
absence of phonophobia (204 [58%] of 353 vs. 126 [37%]
of 342 [P \ 0.0001]), photophobia (180 [51%] of 353 vs.
99 [29%] of 342 [P \ 0.0001]), and nausea (229 [65%] of
352 vs. 189 [55%] of 342 [P = 0.0061]). The efficacy of
telcagepant 300 mg and zolmitriptan 5 mg were much the
same, and both were more effective than telcagepant
150 mg. Adverse events were recorded for 31% taking
telcagepant 150 mg, 37% taking telcagepant 300 mg, 51%
taking zolmitriptan 5 mg, and 32% taking placebo.’’ The
measurement of 2–24 h sustained pain freedom was
slightly better numerically for telcagepant 300 mg versus
zolmitriptan 5 mg, but there was no statistical difference.
S50 Neurol Sci (2009) 30 (Suppl 1):S49–S54
123
A potential benefit of telcagepant and other CGRP
receptor antagonists is the lack of vasoconstriction in ani-
mal models. This suggests that they may be able to be
given to patients with vascular disease, but that was not
studied in this trial as zolmitriptan is contraindicated in
patients with vascular disease and will have to be studied in
the future.
Transdermal patches
Recently, sumatriptan became the first of the seven triptans
to become generic in several countries, which has led to the
development of generic formulations of available products
and to the design of some novel products containing the
generic formulation, including needle-less injection, sub-
lingual, intranasal and patch forms. One of the most
interesting products in development, which may address
the unmet need of the nauseated migraineur and/or the
patient who does not absorb oral medication optimally
during a migraine attack, is a sumatriptan patch. NP101,
from NuPathe, is an iontophoretic patch that delivers
sumatriptan transdermally. It utilizes a small electric cur-
rent to drive sumatriptan across the skin delivering 6 or
12 mA/h and maintaining sumatriptan plasma levels above
the target level of C10 ng/ml for greater than 7 h [7]. There
is a linear relationship between the applied current and
drug delivery. As a result, drug delivery is precisely con-
trolled at desired levels, providing consistent therapeutic
drug levels. In pK studies, the patch delivered sumatriptan
more consistently than either the 100 mg oral tablet or 20 mg
nasal preparation. This finding supports the hypothesis that
parenteral administration (subcutaneous or transdermal)
provides more predictable delivery by bypassing absorption
through the GI tract.
At the intended plasma concentrations delivered by the
patch, which were in between those of the 20 mg nasal
spray and 100 mg oral tablet, the patches were well tol-
erated. No subject reported atypical pain and pressure
sensations or other common triptan adverse events after
application of NP101 patches. The most common adverse
event for NP101 was application site-related pruritus,
which was generally mild and resolved without treatment.
No subject withdrew from the study due to local skin
irritation. The data suggest that transdermal iontophoretic
delivery of sumatriptan with NP101 may offer significant
clinical utility for migraine patients, including circum-
venting underlying migraine-associated GI disturbances
including nausea and gastric stasis. The patch also provides
consistent, predictable delivery of desired drug levels over
a 4 h period. This offers the potential to avoid atypical
pain, pressure and other sensations commonly associated
with current triptan formulations.
Oral inhalers
Three drugs are being tested as inhalers: DHE, prochlor-
perazine and loxapine. The last two are dopamine antago-
nists, a class of drugs that has been shown to treat migraine
acutely when given intravenously. DHE (dihydroergota-
mine mesylate) has been available in various forms for over
50 years and still remains the mainstay of treatment at
major headache centers in the US when patients require
hospitalization or comes to the emergency room after
having already developed central sensitization. It is usually
given several times per day intravenously. It is also used
orally in Europe as a preventive and intranasally in the US
and Canada as an acute care medication. The intravenous
preparation is often very effective, but cannot be used at
home and often causes the patient to become more nause-
ated or even vomit, in spite of pretreatment with an antie-
metic. Oral inhalation seems to provide similar efficacy
with the ease of home use and fewer adverse events.
Studies were performed with a specially designed device
called the Tempo Inhaler (MAP Pharma), to deliver DHE
deep into the lung after breath actuation [8].
A phase I study of four doses of orally inhaled DHE
delivered by the specially designed inhaler versus 1 mg of
IV DHE (n = 18) was performed. There was a rapid sys-
temic absorption of DHE with a tmax of 12 min with a
0.88 mg respirable dose (vs. a 6 min tmax with the IV
preparation). The systemic levels attained were slightly
lower than with IV DHE, with the ratio of AUC 0-infinity of
inhaled versus IV approximately 0.77. The Tempo inhaler
is a proprietary, novel, breath-actuated device that is
expected to deliver most of the drug to the deep lung,
thereby minimizing oropharyngeal deposition. Phase II data
suggest an onset of action comparable to IV administration
of DHE, with relief that is both rapid and sustained [9].
Phase II results demonstrate that 32% of patients achieve
pain relief as early as 10 min (P = 0.019) at 0.5 mg dose.
This is somewhat lower that the usual dose IV.
DHE delivered by this inhaler was well tolerated in
phase II studies with no serious adverse events. There was
decreased nausea and no clinically significant changes
observed in pulmonary function tests, clinical lab findings,
heart rate, blood pressure or respiratory rate. Phase III
studies are ongoing and have been designed to confirm that
the onset of action is 10 min versus placebo, that there is
sustained pain relief and freedom over 24 and 48 h, with
good safety and tolerability.
Nasal sprays
There are three nasal sprays currently in use for the acute
treatment of migraine in the US, including two triptans,
Neurol Sci (2009) 30 (Suppl 1):S49–S54 S51
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sumatriptan and zolmitriptan and DHE. Intranasal ketoro-
lac has been studied in a convenient, single dose device in a
formulation specifically designed for episodic use. It pro-
vides a pK profile equivalent to that of ketorolac admin-
istered intramuscularly. Ketorolac is a racemic NSAID,
which inhibits the cyclooxygenase system (COX 1 and
COX 2), and hence prostaglandin synthesis, with potent
analgesic and moderate anti-inflammatory activity. It is
highly water soluble and can be delivered in an amount
suitable for intranasal administration (100 ll).
In a phase I, single dose, five-way crossover, random-
ized study, absorption of ketorolac started immediately,
and median tmax ranged from 0.50 to 0.75 h postdose,
irrespective of the dose of ketorolac [10]. There was a
terminal phase half-life of approximately 5–6 h. Very
similar profiles were observed for the IM doses.
Ketorolac has no active metabolites and is metabolized
in the liver by glucuronidation and parahydroxylation.
Further studies compared the pharmacokinetics of intra-
nasal versus intramuscular dosing. ROX-828, from Roxro,
is a nasal spray formulation of ketorolac composed of
30 mg ? 12 mg lidocaine, which reduces nasal irritation.
The pK profile is equal to or better than ketorolac given
intramuscularly. The preparation utilizes a single dose
device with two available sprays. The plasma concentration
curves show that this intranasal formulation achieves peak
blood levels faster than IM injections.
A phase II trial, done in Germany and Finland, consisted
of a double-blind, placebo- controlled, randomized, single
dose study using 30 mg of ketorolac.
The primary endpoint was 2 h pain freedom. The n was
ROX-828 = 68 and placebo = 73. The primary end point
just missed significance (if 3 outlier patients were removed,
the primary endpoint was significant at 2 h). Pain relief was
significant at 1, 1.5, 2, 3 and 4 h. An intranasal dose of
30 mg produced plasma level roughly equivalent to 20 mg
intramuscularly. Further studies are planned, possibly with
a higher dose.
Gap junction blocker (preventive)
Tonabersat is a novel benzoyl-aminobenzopyran anticon-
vulsant and antimigraine medication developed by
SmithKline Beecham. It binds selectively with high affinity
to a unique stereoselective site on neurons and glia. It has no
affinity for any other previously established antiepilepsy or
antimigraine site. Tonabersat inhibits cortical spreading
depression number and duration. Unpublished studies with
carabersat (a close structural analog) in a rat hippocampal
slice model, demonstrated that the action of the class is
related to the inhibition of neuronal-glial gap junctions.
There was also inhibition of electrical coupling of
GABAergic inter-neurons. Tonabersat is 2–3 times more
potent than carabersat. Recent rat trigeminal ganglion
research in vivo indicated that the effect of tonabersat on
gap junctions (hemi-channel communication) is mediated
by connexin 26.
Early studies were done for acute treatment of migraine
and only showed a trend for efficacy. A trial investigated the
efficacy of SB-220453 in the glyceryltrinitrate (GTN) human
experimental migraine model [11]. The study reported, ‘‘15
patients with migraine without aura entered a randomized,
double-blind, crossover study with 40 mg or placebo fol-
lowed by a 20-min GTN infusion. Four subjects had a
hypotensive episode after SB-220453 plus GTN but none
after GTN alone. The reaction was unexpected, since animal
models and previous human studies had shown no vascular
or sympatholytic activity with SB-220453. The study was
terminated prematurely because of this interaction. SB-
220453 had no significant pre-emptive anti-migraine activity
compared with placebo in this human model of migraine.’’
Tonabersat was then studied as a preventive migraine
agent. According to the Minster Pharmaceuticals website,
‘‘Tonabersat completed a phase IIA clinical trial in pro-
phylaxis (prevention) of migraine in 2007. Positive data
from this study include a significant increase in subjects
classed as ‘responders’—defined as a 50% or greater
reduction in migraine attacks at the end of the 3 months of
treatment—on tonabersat compared with those on placebo.
The figures were 62% for tonabersat compared with 45%
for placebo (P \ 0.05).’’
A double-blind, controlled, randomized clinical trial of
migraine with and without aura was performed in patients
on no preventive migraine medication. The doses were
20–40 mg, given once daily, for 3 months. The reduction
in migraine days was 3.7 days for placebo and 4.4 days for
tonabersat, which was not significant. Adverse events were
generally mild and the drug was well tolerated. Fifty-one
percent of placebo patients and 61% of tonabersat patients
had treatment-emergent AEs. Treatment-related adverse
events were 15% for placebo and 39% for tonabersat.
Adverse events leading to withdrawal were two for ton-
abersat (nausea and dizziness) and one for placebo (dizzi-
ness and memory impairment). There were no laboratory
abnormalities. Apparently, a phase IIB trial did not meet its
primary endpoint as announced by Minster Pharmaceuti-
cals in early February 2009. The future development of this
migraine medication is unclear.
Neurotoxin therapy: botulinum toxin injections
(preventive)
Although the exact mechanism of action of botulinum
toxin type A injections as a treatment for headache are not
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known, it is thought that that the antinociceptive action is
probably independent of its anti-cholinergic effects at the
neuromuscular junction. It is no longer believed that the
relaxation or induced weakness of muscles contributes to
the therapeutic effect. Instead inhibition of peripheral
sensitization, leading to the inhibition of central sensiti-
zation through the blocking of glutamate, substance P and
CGRP peripherally, is thought to lead to the therapeutic
effect. There have been many positive open trials and a
few double-blind, controlled studies with conflicting
reports of efficacy. In a chronic migraine trail, in which
the primary endpoint was not reached, efficacy was
shown only in a subgroup not taking preventive medica-
tion [12].
A recent study to compare the effectiveness of treat-
ment of transformed migraine between botulinum toxin
type A and topiramate demonstrated that both groups had
significantly fewer headaches compared with baseline
6 months after the start of therapy. At 9 months, the two
treatments were equivalent. More patients in the topira-
mate group dropped out of the study due to adverse
events [13]. Another recent study compared botulinum
toxin type A with divalproex in episodic and chronic
migraine. The data demonstrate that both treatments
showed a significant reduction in disability with fewer
adverse events in the botulinum toxin type A treated
group [14].
Two large, double-blind, placebo-controlled, random-
ized phase III trials were performed in patients with
chronic migraine according to the IHS definition who
were not on preventive medication. Although the results
have not been released or published, a press release was
issued by Allergan in September 2008 about the results
[15].
The primary endpoint for the first trial was change from
baseline in the number of headache episodes at the end of
3 months. In the second trial, the primary endpoint was
the change in number of headache days in a 28-day period
at the end of 3 months. In the second phase III study,
the primary endpoint and secondary endpoint showed sta-
tistically significant benefit of botulinum toxin type A
treatment over placebo injections. Patients treated with
botulinum toxin type A demonstrated a greater decrease in
both number of headache days (P \ 0.001) (primary end-
point) and number of headache episodes (P = 0.003)
(secondary endpoint). However, the first phase III study did
not meet its primary endpoint. It is thought that if the FDA
suggested endpoint had been used (decrease in number of
headache days), the first study would also have been sig-
nificant. It is suspected that Allergan will file for an indi-
cation for treatment of chronic migraine with botulinum
toxin type A sometime in 2009, based on these two phase
III studies.
Conclusion
There are many new acute care and preventive therapies
being investigated for the treatment of migraine. A few of
them, which should be available in the near future, have
been presented here. I am cautiously optimistic that some
of them will make it to the clinic and will be effective
additions to the headache specialist’s armamentarium.
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